Abel Kakuru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abel Kakuru has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Grant Dorsey
Department of Medicine, University of California San Francisco , San Francisco, California
21 shared publications - Moses Robert Kamya
School of Medicine, Makerere University, Kampala, Uganda
21 shared publications - Prasanna Jagannathan
Stanford University
18 shared publications - Joaniter Immaculate Nankabirwa
Infectious Diseases Research Collaboration , Kampala
9 shared publications - Mary Kakuru Muhindo
Infectious Diseases Research Collaboration, Kampala, Uganda
9 shared publications Grant Dorsey
Department of Medicine, University of California
8 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Low Birthweight and Prematurity, but not Malaria Chemoprevention, Are Associated With Reduced Pneumococcal Vaccine Immunogenicity in Ugandan Infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8- and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (ie, seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention, and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500 g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43–94%] antibody fold-change, P = .003) and reduced odds of seroconversion (OR = 0.19 [95% CI: 0.06–0.57], P = .003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24–94%] antibody fold-change, P = .018; OR = 0.181 [95% CI: 0.05–0.65], P = .009). Conclusions: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
- 28 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessLow Birthweight and Prematurity, but not Malaria Chemoprevention, Are Associated With Reduced Pneumococcal Vaccine Immunogenicity in Ugandan Infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8- and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (ie, seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention, and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500 g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43–94%] antibody fold-change, P = .003) and reduced odds of seroconversion (OR = 0.19 [95% CI: 0.06–0.57], P = .003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24–94%] antibody fold-change, P = .018; OR = 0.181 [95% CI: 0.05–0.65], P = .009). Conclusions: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
- Open Access
- 5 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Prevalence of Congenital Cytomegalovirus Infection in a CMV-Endemic Ugandan Population
Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood deafness and disability worldwide. However, less is known about its epidemiology in low-income regions where most women are CMV-seropositive at conception. We found that cCMV is highly prevalent in rural Uganda (3.73%) and is associated with lower gravidity and placental malaria. We additionally report a high transmission intensity in the first years of life, with 97.3% of children acquiring CMV IgG by age 3.
- 5 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessPrevalence of Congenital Cytomegalovirus Infection in a CMV-Endemic Ugandan Population
Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood deafness and disability worldwide. However, less is known about its epidemiology in low-income regions where most women are CMV-seropositive at conception. We found that cCMV is highly prevalent in rural Uganda (3.73%) and is associated with lower gravidity and placental malaria. We additionally report a high transmission intensity in the first years of life, with 97.3% of children acquiring CMV IgG by age 3.
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
The Value of Ultrasound in Improving Gestational Age Estimates and Impact on Accuracy of Maternal-Child Health Metrics in Rural Uganda
Background: In resource-limited settings, pregnancy dating often relies on the last menstrual period (LMP). Gestational age (GA) is best confirmed by ultrasound. The value of ultrasound for improving population-level maternal health indicators remains understudied.Methods: This was a cohort study of 2,757 pregnant women enrolled in a trial comparing intermittent preventative treatments for malaria. Ultrasound was performed between 12–20 weeks gestation to confirm GA. Final estimated due date (F-EDD) was determined using established standards to assess discordance between LMP-based (LMP-EDD) and ultrasound-based (US-EDD) EDD. We compared LMP-EDD with F-EDD for estimating preterm birth (PTB) and small for gestational age (SGA) prevalence.Results: Among 2,757 participants, 1,566 (56 8%) had unknown LMP and were dated by ultrasound. Among 1,191 with known LMP, 253 (21 2%) were redated by ultrasound, of whom 229 had live births. PTB prevalence was higher using LMP-EDD than F-EDD (7 3% vs 5 2%, p=<0 001). SGA prevalence did not differ significantly (22% vs. 23 1%, p=0.05). Among participants with LMP-EDD redated by ultrasound, prevalence of PTB was overestimated nearly fourfold by LMP compared to ultrasound (13 1% vs. 3 5%, p=<0 001); SGA rates were similar (17 9% vs. 23 1%, p=0 05).Interpretation: Reliance on LMP-EDD overestimated PTB prevalence, underscoring the value of ultrasound for accurate maternal health surveillance.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Value of Ultrasound in Improving Gestational Age Estimates and Impact on Accuracy of Maternal-Child Health Metrics in Rural Uganda
Background: In resource-limited settings, pregnancy dating often relies on the last menstrual period (LMP). Gestational age (GA) is best confirmed by ultrasound. The value of ultrasound for improving population-level maternal health indicators remains understudied.Methods: This was a cohort study of 2,757 pregnant women enrolled in a trial comparing intermittent preventative treatments for malaria. Ultrasound was performed between 12–20 weeks gestation to confirm GA. Final estimated due date (F-EDD) was determined using established standards to assess discordance between LMP-based (LMP-EDD) and ultrasound-based (US-EDD) EDD. We compared LMP-EDD with F-EDD for estimating preterm birth (PTB) and small for gestational age (SGA) prevalence.Results: Among 2,757 participants, 1,566 (56 8%) had unknown LMP and were dated by ultrasound. Among 1,191 with known LMP, 253 (21 2%) were redated by ultrasound, of whom 229 had live births. PTB prevalence was higher using LMP-EDD than F-EDD (7 3% vs 5 2%, p=<0 001). SGA prevalence did not differ significantly (22% vs. 23 1%, p=0.05). Among participants with LMP-EDD redated by ultrasound, prevalence of PTB was overestimated nearly fourfold by LMP compared to ultrasound (13 1% vs. 3 5%, p=<0 001); SGA rates were similar (17 9% vs. 23 1%, p=0 05).Interpretation: Reliance on LMP-EDD overestimated PTB prevalence, underscoring the value of ultrasound for accurate maternal health surveillance.
- Open Access
- 7 June 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Congenital cytomegalovirus infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors
Gamma delta (γδ) T cells emerge early during human gestation and are uniquely equipped to protect the fetus and infant following infection, due to their innate-like recognition of conserved molecular ligands. Following congenital cytomegalovirus infection (cCMV), Vδ1 T cells have been shown to expand, differentiate, and upregulate cytotoxic mediators, but display markedly restricted γδTCR diversity compared to CMV-infected adults. Early fetal γδ T cells are biased toward rapid effector function and comprise a distinct ontological “layer” that can be distinguished from late gestation γδ T cells based on TCR characteristics. To better understand the contribution of fetal γδ T cells to antiviral defense in utero, we analyzed γδ T cells from cCMV+ and uninfected neonates in Uganda using flow cytometry and paired single-cell RNA and TCR sequencing. We observed that in cCMV+ neonates, γδ T cells clonally proliferate and differentiate into a uniform population of cytotoxic effectors. The expanded Vδ1 population is comprised of diverse clonotypes with broad Vγ chain usage, with a striking correlation between expansion and publicity. Overall, γδTCR repertoires of cCMV+ infants have shorter CDR3 lengths and fewer N additions, suggesting they derive from early fetal progenitor cells. In cCMV+ infants, most cells with fetal γδTCR characteristics are effector-differentiated, whereas in uninfected infants, such cells are rare and predominantly naïve. Together, these findings demonstrate that cCMV infection drives an oligoclonal expansion of highly cytotoxic effector γδ T cells with fetal-like TCR features, illustrating how the developing immune system prioritizes broad reactivity and rapid effector function over specificity.
- 7 June 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Open AccessCongenital cytomegalovirus infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors
Gamma delta (γδ) T cells emerge early during human gestation and are uniquely equipped to protect the fetus and infant following infection, due to their innate-like recognition of conserved molecular ligands. Following congenital cytomegalovirus infection (cCMV), Vδ1 T cells have been shown to expand, differentiate, and upregulate cytotoxic mediators, but display markedly restricted γδTCR diversity compared to CMV-infected adults. Early fetal γδ T cells are biased toward rapid effector function and comprise a distinct ontological “layer” that can be distinguished from late gestation γδ T cells based on TCR characteristics. To better understand the contribution of fetal γδ T cells to antiviral defense in utero, we analyzed γδ T cells from cCMV+ and uninfected neonates in Uganda using flow cytometry and paired single-cell RNA and TCR sequencing. We observed that in cCMV+ neonates, γδ T cells clonally proliferate and differentiate into a uniform population of cytotoxic effectors. The expanded Vδ1 population is comprised of diverse clonotypes with broad Vγ chain usage, with a striking correlation between expansion and publicity. Overall, γδTCR repertoires of cCMV+ infants have shorter CDR3 lengths and fewer N additions, suggesting they derive from early fetal progenitor cells. In cCMV+ infants, most cells with fetal γδTCR characteristics are effector-differentiated, whereas in uninfected infants, such cells are rare and predominantly naïve. Together, these findings demonstrate that cCMV infection drives an oligoclonal expansion of highly cytotoxic effector γδ T cells with fetal-like TCR features, illustrating how the developing immune system prioritizes broad reactivity and rapid effector function over specificity.
- Open Access
Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial ( NCT04978272 ) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log 10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19, p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower antibody fold-change, p=0.018; OR=0.181, p=0.009). Conclusion: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
Open AccessLow birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial ( NCT04978272 ) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log 10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19, p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower antibody fold-change, p=0.018; OR=0.181, p=0.009). Conclusion: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
- Open Access
- 6 May 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 114 (5) , 905-912
Natural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda
: Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.
- 6 May 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 114 (5) , 905-912
Open AccessNatural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda
: Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.
- Open Access
- 20 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e757-e765
Impact of Intermittent Preventive Treatment for Malaria in Pregnancy With Sulfadoxine-Pyrimethamine, Dihydroartemisinin-Piperaquine, and Their Combination on Infant Outcomes: A Randomized Controlled Trial
Background: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) is more effective than sulfadoxine-pyrimethamine (IPTp-SP) at reducing the burden of malaria in pregnancy. Paradoxically, IPTp-DP has been associated with lower birth weights compared with IPTp-SP. Whether the impacts of IPTp-DP extend after birth is unknown. Methods: We conducted a double-blind randomized controlled trial to compare malaria burden and growth among infants born to mothers who were randomized to monthly IPTp-SP, IPTp-DP, or IPTp-DP + SP. Infants were followed to 12 months of age by passive and active surveillance. The primary outcome was clinical malaria incidence; secondary outcomes included parasite prevalence and infant growth outcomes. Results: Among 871 infants enrolled, there were 667 episodes of clinical malaria. Compared to infants whose mothers received IPTp-SP, malaria incidence was similar in infants whose mothers received IPTp-DP (incidence rate ratio [IRR] 1.04, 95% CI .78–1.38) or IPTp-DP + SP (IRR = 0.93, 95% CI .68–1.26). Overall parasite prevalence at monthly visits was 21.8%. Parasite prevalence was also similar between groups. The prevalence of wasting at birth was higher in infants whose mothers received IPTp-DP + SP (prevalence ratio [PR] = 2.30, 95% CI 1.07–4.97) or IPTp-DP (PR = 2.25, 95% CI 1.03–4.94) than those that received IPTp-SP, but differences between groups resolved by 3–6 months of age. Conclusions: There were no significant differences in infant outcomes between the 3 IPTp arms apart from a transiently increased risk of wasting among infants born to mothers who received DP-containing IPTp regimens.
- 20 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e757-e765
Open AccessImpact of Intermittent Preventive Treatment for Malaria in Pregnancy With Sulfadoxine-Pyrimethamine, Dihydroartemisinin-Piperaquine, and Their Combination on Infant Outcomes: A Randomized Controlled Trial
Background: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) is more effective than sulfadoxine-pyrimethamine (IPTp-SP) at reducing the burden of malaria in pregnancy. Paradoxically, IPTp-DP has been associated with lower birth weights compared with IPTp-SP. Whether the impacts of IPTp-DP extend after birth is unknown. Methods: We conducted a double-blind randomized controlled trial to compare malaria burden and growth among infants born to mothers who were randomized to monthly IPTp-SP, IPTp-DP, or IPTp-DP + SP. Infants were followed to 12 months of age by passive and active surveillance. The primary outcome was clinical malaria incidence; secondary outcomes included parasite prevalence and infant growth outcomes. Results: Among 871 infants enrolled, there were 667 episodes of clinical malaria. Compared to infants whose mothers received IPTp-SP, malaria incidence was similar in infants whose mothers received IPTp-DP (incidence rate ratio [IRR] 1.04, 95% CI .78–1.38) or IPTp-DP + SP (IRR = 0.93, 95% CI .68–1.26). Overall parasite prevalence at monthly visits was 21.8%. Parasite prevalence was also similar between groups. The prevalence of wasting at birth was higher in infants whose mothers received IPTp-DP + SP (prevalence ratio [PR] = 2.30, 95% CI 1.07–4.97) or IPTp-DP (PR = 2.25, 95% CI 1.03–4.94) than those that received IPTp-SP, but differences between groups resolved by 3–6 months of age. Conclusions: There were no significant differences in infant outcomes between the 3 IPTp arms apart from a transiently increased risk of wasting among infants born to mothers who received DP-containing IPTp regimens.
- Open Access
- 19 January 2026
- Published by SAGE Publications in International Journal of Qualitative Methods
- Vol. 25
Development of Context-Appropriate Recruitment and Retention Approaches for Pregnant Women in the SAFIRE Clinical Trial Assessing Safety and Efficacy of Artemisinin-Combination Therapies: A Formative Research Protocol
Pregnant women, particularly those in the first trimester, have been historically excluded from clinical trials, resulting in substantial evidence gaps for the prevention and treatment of malaria in early pregnancy. Despite increasing calls from global health and regulatory bodies to include pregnant women in research, ethical, socio-cultural, and contextual challenges continue to impede their meaningful participation. Formative research is essential to understanding these challenges and informing trial procedures that are ethically robust and contextually appropriate. This study aims to explore stakeholder perceptions, beliefs, and decision-making processes related to early pregnancy and participation in clinical trials, to inform the development of culturally sensitive recruitment, retention, and community engagement strategies for the multi-country SAFIRE clinical trial on the safety and efficacy of artemisinin-combination therapies. Qualitative methods include in-depth interviews and focus group discussions with purposively sampled women of childbearing age, pregnant women, health providers and managers, community leaders, and other key health decision-makers. Data will be collected across five malaria-endemic countries in sub-Saharan Africa. A reflexive thematic analysis approach will be used, combining inductive and deductive coding within a collaboratively developed coding framework. Analysis will be informed by a Theory of Change to examine how identified barriers and facilitators may influence pathways to successful recruitment and retention. This protocol demonstrates how formative research can be systematically integrated into clinical trials to support the ethical inclusion of pregnant women.
- 19 January 2026
- Published by SAGE Publications in International Journal of Qualitative Methods
- Vol. 25
Open AccessDevelopment of Context-Appropriate Recruitment and Retention Approaches for Pregnant Women in the SAFIRE Clinical Trial Assessing Safety and Efficacy of Artemisinin-Combination Therapies: A Formative Research Protocol
Pregnant women, particularly those in the first trimester, have been historically excluded from clinical trials, resulting in substantial evidence gaps for the prevention and treatment of malaria in early pregnancy. Despite increasing calls from global health and regulatory bodies to include pregnant women in research, ethical, socio-cultural, and contextual challenges continue to impede their meaningful participation. Formative research is essential to understanding these challenges and informing trial procedures that are ethically robust and contextually appropriate. This study aims to explore stakeholder perceptions, beliefs, and decision-making processes related to early pregnancy and participation in clinical trials, to inform the development of culturally sensitive recruitment, retention, and community engagement strategies for the multi-country SAFIRE clinical trial on the safety and efficacy of artemisinin-combination therapies. Qualitative methods include in-depth interviews and focus group discussions with purposively sampled women of childbearing age, pregnant women, health providers and managers, community leaders, and other key health decision-makers. Data will be collected across five malaria-endemic countries in sub-Saharan Africa. A reflexive thematic analysis approach will be used, combining inductive and deductive coding within a collaboratively developed coding framework. Analysis will be informed by a Theory of Change to examine how identified barriers and facilitators may influence pathways to successful recruitment and retention. This protocol demonstrates how formative research can be systematically integrated into clinical trials to support the ethical inclusion of pregnant women.
- Open Access
Congenital CMV infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors
Gamma delta T cells (γδ T cells) emerge early during human gestation and are uniquely equipped to protect the fetus and infant following in utero infection with viruses such as cytomegalovirus (CMV). Previous research showed that fetal γδ T cells in early gestation are transcriptionally pre-programmed for effector functions in the thymus. Infants with congenital CMV infection (cCMV) exhibit expansions of γδ T cells with CMV-reactive TCRs; however, the functional and transcriptional programming of these innate-like effector cells has not been characterized. Here, we analyzed cord blood mononuclear cells from cCMV+ and uninfected neonates in Uganda using flow cytometry and single-cell RNA and TCR sequencing. We find that γδ T cells in cCMV+ neonates are more differentiated, activated, cytotoxic, and proliferative. TCR repertoires of cCMV+ infants exhibit oligoclonal expansions with an enrichment of γδTCRs that possess shorter CDR3 lengths and fewer N additions, which suggest they arise from early fetal progenitor cells. These expanded γδ T cell clonotypes in cCMV+ infants are more frequently public and exhibit cytotoxic transcriptional programming. These findings demonstrate that cCMV infection drives an oligoclonal expansion of highly cytotoxic effector γδ T cells with fetal-like TCR features, underscoring their specialized roles in early-life immunity.
Open AccessCongenital CMV infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors
Gamma delta T cells (γδ T cells) emerge early during human gestation and are uniquely equipped to protect the fetus and infant following in utero infection with viruses such as cytomegalovirus (CMV). Previous research showed that fetal γδ T cells in early gestation are transcriptionally pre-programmed for effector functions in the thymus. Infants with congenital CMV infection (cCMV) exhibit expansions of γδ T cells with CMV-reactive TCRs; however, the functional and transcriptional programming of these innate-like effector cells has not been characterized. Here, we analyzed cord blood mononuclear cells from cCMV+ and uninfected neonates in Uganda using flow cytometry and single-cell RNA and TCR sequencing. We find that γδ T cells in cCMV+ neonates are more differentiated, activated, cytotoxic, and proliferative. TCR repertoires of cCMV+ infants exhibit oligoclonal expansions with an enrichment of γδTCRs that possess shorter CDR3 lengths and fewer N additions, which suggest they arise from early fetal progenitor cells. These expanded γδ T cell clonotypes in cCMV+ infants are more frequently public and exhibit cytotoxic transcriptional programming. These findings demonstrate that cCMV infection drives an oligoclonal expansion of highly cytotoxic effector γδ T cells with fetal-like TCR features, underscoring their specialized roles in early-life immunity.
- Open Access
Recurrent Plasmodium falciparum parasitemia and drug resistance mutations during intermittent preventive treatment of malaria in pregnancy in Uganda
Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is of interest. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP+SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP+SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP+SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.
Open AccessRecurrent Plasmodium falciparum parasitemia and drug resistance mutations during intermittent preventive treatment of malaria in pregnancy in Uganda
Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is of interest. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP+SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP+SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP+SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.